U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

By Sabrina Valle NEW YORK (Reuters) -Healthcare dealmakers gathering in San Francisco for the industry's premier annual ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

The trial showed a 'clinically meaningful' and 'statistically significant' improvement when treated with therapy plus BCG, ...

We recently compiled a list of the 12 Most Reliable Dividend Stocks To Buy According to Hedge Funds. In this article, we are ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of ...

Pfizer PFE announced positive results from the phase III CREST study that evaluated its investigational PD-1 inhibitor ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.

UK women report significant breast enlargement after Pfizer COVID-19 vaccine. Possible link to rare condition PASH, but requires further research.

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

At $132 per share, J&J paid a 39% premium on Friday’s closing price of Intra-Cellular, a New York City based biotech that ...